LOS ANGELES, March 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative ...
Acelyrin (NASDAQ:SLRN) announced Thursday a decision to adopt a limited-duration stockholder rights plan, also known as a poison pill, after Tang Capital Partners rapidly accumulated 8.8% of the ...
Acelyrin (NASDAQ:SLRN) traded sharply lower on Tuesday after the company and its California-based rival Alumis (NASDAQ:ALMS) reaffirmed their commitment to merge in line with their previously ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback